Stock Track | Eli Lilly Plunges 5.07% in Pre-market as Weight-Loss Drug Sector Faces Pressure from Novo Nordisk Guidance Disappointment

Stock Track

Feb 05

Eli Lilly's stock experienced a significant pre-market plunge of 5.07% on Thursday, as negative sentiment swept through the weight-loss drug sector following disappointing guidance from a key competitor.

The sharp decline came despite multiple analyst upgrades for Eli Lilly, with firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo all raising their price targets on the pharmaceutical company following its strong fourth-quarter earnings report.

The sector-wide pressure appears to stem from Novo Nordisk's disappointing outlook for the year ahead, which caused its shares to tumble 19% at the opening bell in Copenhagen. As a major competitor to Eli Lilly in the GLP-1 weight-loss drug market, Novo Nordisk's guidance disappointment has raised concerns about the broader weight-loss drug sector, overshadowing Eli Lilly's own positive results and analyst upgrades.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145413327"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145413327\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145413327?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145413327","market":"sg","top_or_hot":-1,"title":"Stock Track | Eli Lilly Plunges 5.07% in Pre-market as Weight-Loss Drug Sector Faces Pressure from Novo Nordisk Guidance Disappointment","media":"Stock Track","content":"<p>Eli Lilly's stock experienced a significant pre-market plunge of 5.07% on Thursday, as negative sentiment swept through the weight-loss drug sector following disappointing guidance from a key competitor.</p><p>The sharp decline came despite multiple analyst upgrades for Eli Lilly, with firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo all raising their price targets on the pharmaceutical company following its strong fourth-quarter earnings report.</p><p>The sector-wide pressure appears to stem from Novo Nordisk's disappointing outlook for the year ahead, which caused its shares to tumble 19% at the opening bell in Copenhagen. As a major competitor to Eli Lilly in the GLP-1 weight-loss drug market, Novo Nordisk's guidance disappointment has raised concerns about the broader weight-loss drug sector, overshadowing Eli Lilly's own positive results and analyst upgrades.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Plunges 5.07% in Pre-market as Weight-Loss Drug Sector Faces Pressure from Novo Nordisk Guidance Disappointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Plunges 5.07% in Pre-market as Weight-Loss Drug Sector Faces Pressure from Novo Nordisk Guidance Disappointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 22:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly's stock experienced a significant pre-market plunge of 5.07% on Thursday, as negative sentiment swept through the weight-loss drug sector following disappointing guidance from a key competitor.</p><p>The sharp decline came despite multiple analyst upgrades for Eli Lilly, with firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo all raising their price targets on the pharmaceutical company following its strong fourth-quarter earnings report.</p><p>The sector-wide pressure appears to stem from Novo Nordisk's disappointing outlook for the year ahead, which caused its shares to tumble 19% at the opening bell in Copenhagen. As a major competitor to Eli Lilly in the GLP-1 weight-loss drug market, Novo Nordisk's guidance disappointment has raised concerns about the broader weight-loss drug sector, overshadowing Eli Lilly's own positive results and analyst upgrades.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1145413327","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145413327","pubTimestamp":1770300179,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly's stock experienced a significant pre-market plunge of 5.07% on Thursday, as negative sentiment swept through the weight-loss drug sector following disappointing guidance from a key...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"个股追踪|礼来盘前暴跌5.07%减肥药板块面临诺和诺德指引失望压力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly's stock experienced a significant pre-market plunge of 5.07% on Thursday, as negative sentiment swept through the weight-loss drug sector following disappointing guidance from a key competitor.The sharp decline came despite multiple analyst upgrades for Eli Lilly, with firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo all raising their price targets on the pharmaceutical company following its strong fourth-quarter earnings report.The sector-wide pressure appears to stem from Novo Nordisk's disappointing outlook for the year ahead, which caused its shares to tumble 19% at the opening bell in Copenhagen. As a major competitor to Eli Lilly in the GLP-1 weight-loss drug market, Novo Nordisk's guidance disappointment has raised concerns about the broader weight-loss drug sector, overshadowing Eli Lilly's own positive results and analyst upgrades.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}